Thomas Graham, Alan, Irving Kahns
Kahn Brothers Group
Kahn Brothers Group Portfolio 13F
Kahn Brothers Group Holdings Activity
- Portfolio value:
- $573.28M≈ (+$46M≈)
- Previous value:
- $527.50M≈
- # of changes:
- 31
- New positions:
- 1
- Reported for:
- 31 Dec 2020 (Q4)
- Latest filing date:
- 11 Feb 2021
Kahn Brothers Group has disclosed a total of 31 changes to the portfolio in the (2020 Q4) SEC report(s): increased the number of shares of 3, bought 1 totally new, decreased the number of shares of 26 and completely sold out 1 position(s).
What did Kahn Brothers Group invest in during 2020 Q4?
In the 2020 Q4 report(s) the following changes have been made to the top investments: (MRK) Merck & Company Inc (reduced shares -8.93%), (BMY) Bristol-Myers Squibb Company (reduced shares -7.66%), (C) Citigroup Inc (reduced shares -4.04%), (AGO) ASSURED GUARANTY LTD (reduced shares -8.26%) and (GSK) GlaxoSmithKline PLC ADR (reduced shares -8.87%).
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
* Current price: this can be a delayed price and may not reflect the real-time market value, however it is too close.
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* Held since / Held for: calculated since the latest "new buy" position. If the security was previously exited and re-entered, only the most recent holding period is counted.